Kamada
$ 7.44
3.19%
11 Jun - close price
- Market Cap 430,151,000 USD
- Current Price $ 7.44
- High / Low $ 7.46 / 7.27
- Stock P/E 21.26
- Book Value 4.50
- EPS 0.35
- Next Earning Report f
- Dividend Per Share $0.25
- Dividend Yield 3.47 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.08 %
- 52 Week High 9.07
- 52 Week Low 6.31
About
Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel.
Analyst Target Price
$13.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-11 | 2025-11-10 | 2025-08-13 | 2025-05-14 | 2025-03-05 | 2024-11-13 | 2024-08-14 | 2024-05-08 | 2024-03-06 | 2023-11-13 | 2023-08-16 |
| Reported EPS | 0.07 | 0.06 | 0.29 | 0.19 | 0.07 | 0.07 | 0.07 | 0.08 | 0.04 | 0.09 | 0.06 | 0.04 |
| Estimated EPS | 0.115 | 0.1 | 0.09 | 0.08 | 0.0675 | 0.0533 | 0.07 | 0.06 | 0.06 | 0.05 | 0.03 | 0.02 |
| Surprise | -0.045 | -0.04 | 0.2 | 0.11 | 0.0025 | 0.0167 | 0 | 0.02 | -0.02 | 0.04 | 0.03 | 0.02 |
| Surprise Percentage | -39.1304% | -40% | 222.2222% | 137.5% | 3.7037% | 31.3321% | 0% | 33.3333% | -33.3333% | 80% | 100% | 100% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Previous Dividend Records
| Apr 2026 | Apr 2025 | |
|---|---|---|
| Payment Date | 2026-04-07 | 2025-04-07 |
| Amount | $0.25 | $0.2 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KMDA
2026-06-11 05:40:48
Kamada Ltd, an Israeli biopharmaceutical company, specializing in plasma-derived products and inhaled therapies, has experienced recent stock weakness despite its strategic focus. The company develops and markets treatments for rare and serious conditions, including alpha-1 antitrypsin (AAT) deficiency and immune deficiencies, primarily in the US and Europe. While recent performance has been volatile, its niche focus and diversified revenue base continue to attract investor attention in the healthcare sector.
2026-06-10 15:10:40
Kamada Ltd, an Israeli biopharma company, continues to focus on specialty plasma-derived products and inhaled therapies despite recent stock weakness. The company develops, manufactures, and markets products for rare and serious conditions, including AAT deficiency and immune deficiencies. Its strategic approach includes proprietary therapies and distribution agreements, aiming for diversified revenue streams and global market presence.
2026-06-02 02:39:01
Kamada Ltd. announced that the U.S. FDA has approved its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory in Israel for potency testing of its anti-rabies products, KEDRAB and KAMRAB. This approval follows prior authorizations from Health Canada and the Israeli Ministry of Health, making it one of the few labs globally capable of performing such tests. The new facility is expected to enhance operational efficiencies and supports the company's strong financial performance, with analysts maintaining bullish targets for its stock.
2026-06-01 11:40:20
Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) announced FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. This state-of-the-art facility, located in Beit Kama, Israel, enhances Kamada's advanced testing capabilities for anti-rabies potency, vital for its KEDRAB® and KAMRAB® products, which generated over $70 million in sales in 2025. The new lab allows for increased operational efficiencies and reinforces Kamada's leadership in specialty plasma-derived therapies.
2026-06-01 11:40:20
Kamada Ltd. announced FDA approval for its new Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory in Israel. This lab will conduct potency testing for their anti-rabies products, KEDRAB and KAMRAB, which generated over $70 million in sales in 2025. The approval is expected to enhance operational efficiencies and follows prior clearances from Health Canada and the Israeli Ministry of Health.
2026-06-01 10:40:20
Kamada Ltd. (NASDAQ: KMDA) announced that the FDA has approved its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory. This lab, located in Israel and previously approved by Health Canada and the Israeli Ministry of Health, will be used for Anti-Rabies potency testing for the company’s KEDRAB and KAMRAB immunoglobulin products, which generated over $70 million in sales in 2025. The approval enhances Kamada's quality control network and operational efficiencies, reinforcing its position as a leader in specialty plasma-derived therapies.
